A gene therapy virus triggered the first documented human tumor

Signals Inbox·July 15, 2026·Gene Therapy

A gene therapy given to a 13-month-old boy appears to have caused a brain tumor four years later. The treatment also protected him from the severe brain damage expected from his disease, creating an uncomfortable first: the clearest human proof that AAV, gene therapy’s supposedly safer delivery virus, can rarely insert into DNA and help start cancer.

Q1What actually happened?

Researchers described the case in The New England Journal of Medicine. A boy with severe MPS I received an experimental AAV9 gene therapy at 13 months old. Four years later, a routine brain scan found a tumor. Surgeons removed it successfully, then researchers analyzed its DNA and found pieces of the therapy’s viral vector inside it.

Q2How strong is the link?

Much stronger than a simple coincidence. Rearranged pieces of the AAV vector had inserted into the child’s DNA near PLAG1, a gene known to drive abnormal cell growth. The tumor also showed unusually high PLAG1 activity. That molecular trail led researchers to conclude that the vector integration was associated with the tumor’s development.

Q3Why is this a first?

Older gene therapies using retroviruses have caused leukemia before because those viruses naturally insert DNA into chromosomes. AAV is different. It became the industry’s favorite delivery vehicle partly because it usually leaves its genetic package outside the chromosomes. This appears to be the first human tumor with direct molecular evidence connecting AAV integration to the cancer.

Q4Does this mean AAV gene therapy is unsafe?

No. It means the risk is real but probably extremely rare. Thousands of people have received AAV-based treatments without this outcome. One case cannot tell us the true rate, and the boy received an experimental treatment delivered directly near the brain at a very young age. Dose, age, tissue type, and delivery method may all matter.

Q5Did the treatment still help him?

Yes, dramatically. The boy had severe Hurler syndrome, which can cause rapid and irreversible damage to the brain and body. His first stem-cell transplant had failed, while a second reportedly carried a 10% to 15% risk of death. After gene therapy, his cognitive development was preserved. His doctors say he reads, loves math, and performs far above what would normally be expected with the disease.

Q6What changes for gene-therapy companies?

The biggest change is time. A tumor appearing four years later means short clinical trials cannot capture every risk. Developers may need deeper integration testing, better tumor surveillance, clearer consent forms, and patient follow-up lasting decades. Regulators will also want to know whether certain AAV designs, doses, injection sites, or young patients carry more risk.

Q7So should I care?

Yes, but this is not a gene-therapy apocalypse. It is one rare case in which a treatment delivered enormous benefits and also appears to have caused a serious harm years later. The real signal is that AAV’s clean safety record is no longer absolute. Gene therapy can still be life-saving, but its patients may need to be watched for much longer than anyone hoped.